공시 • May 14
Cantourage Group SE, Annual General Meeting, Jun 24, 2026 Cantourage Group SE, Annual General Meeting, Jun 24, 2026, at 11:00 W. Europe Standard Time. 공시 • Mar 27
Cantourage Group SE to Report Fiscal Year 2025 Results on May 15, 2026 Cantourage Group SE announced that they will report fiscal year 2025 results at 12:00 PM, Central European Standard Time on May 15, 2026 Price Target Changed • Mar 09
Price target increased by 9.1% to €9.00 Up from €8.25, the current price target is an average from 2 analysts. New target price is 74% above last closing price of €5.18. Stock is up 12% over the past year. New Risk • Sep 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (€2.2m revenue, or US$2.6m). Market cap is less than US$100m (€45.6m market cap, or US$53.5m). Major Estimate Revision • Sep 08
Consensus revenue estimates fall by 13% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from €100.3m to €87.1m. EPS estimate fell from €0.34 to €0.16 per share. Net income forecast to grow 2,359% next year vs 49% growth forecast for Pharmaceuticals industry in Germany. Consensus price target down from €13.00 to €10.25. Share price fell 5.9% to €3.70 over the past week. Price Target Changed • Sep 06
Price target decreased by 18% to €10.25 Down from €12.50, the current price target is an average from 2 analysts. New target price is 177% above last closing price of €3.70. Stock is down 28% over the past year. 공시 • May 19
Cantourage Group SE, Annual General Meeting, Jun 25, 2025 Cantourage Group SE, Annual General Meeting, Jun 25, 2025, at 13:00 W. Europe Standard Time. New Risk • Apr 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Revenue is less than US$5m (€2.0m revenue, or US$2.1m). Market cap is less than US$100m (€55.5m market cap, or US$60.8m). 공시 • Mar 09
Cantourage Group SE to Report First Half, 2025 Results on Oct 31, 2025 Cantourage Group SE announced that they will report first half, 2025 results on Oct 31, 2025 Major Estimate Revision • Jan 29
Consensus estimates of losses per share improve by 33% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €50.3m to €51.4m. EPS estimate increased from -€0.03 per share to -€0.02 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €12.00 to €12.25. Share price rose 4.9% to €5.10 over the past week. Major Estimate Revision • Jan 21
Consensus estimates of losses per share improve by 75% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has improved. 2024 revenue forecast increased from €48.8m to €50.3m. EPS estimate increased from -€0.02 per share to -€0.005 per share. Pharmaceuticals industry in Germany expected to see average net income growth of 31% next year. Consensus price target up from €11.75 to €12.00. Share price was steady at €4.86 over the past week. Price Target Changed • Dec 05
Price target increased by 7.5% to €10.75 Up from €10.00, the current price target is an average from 2 analysts. New target price is 141% above last closing price of €4.46. Stock is down 39% over the past year. Price Target Changed • Jul 18
Price target increased by 10% to €11.00 Up from €10.00, the current price target is provided by 1 analyst. New target price is 59% above last closing price of €6.90. Stock is down 36% over the past year. 공시 • May 17
Cantourage Group SE, Annual General Meeting, Jun 26, 2024 Cantourage Group SE, Annual General Meeting, Jun 26, 2024, at 13:00 W. Europe Standard Time. New Risk • Feb 12
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Shareholders have been diluted in the past year (5.0% increase in shares outstanding). New Risk • Feb 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (11% average weekly change). New Risk • Dec 04
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €92.4m (US$99.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (€92.4m market cap, or US$99.9m). New Risk • Aug 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change). 공시 • Jul 22
Cantourage Group SE Provides Earnings Guidance for the Fiscal Year 2023 Cantourage Group SE provided earnings guidance for the fiscal year 2023. For the year, the company expects sales growth to be in the higher double-digit percentage range compared to the previous year. New Risk • Jun 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Share price has been volatile over the past 3 months (7.2% average weekly change).